VTE and Anticoagulation Therapy

SUMMARY

SHM has selected expert faculty to appear at each conference to present the latest, evidence-based best practices for safely and effectively optimizing anticoagulation therapy during inpatient care and care transitions. NYSPFP adverse drug event conferences are intended to help hospitals implement related protocols and other key interventions. Each session will cover the following:

  • Innovations in performance improvement strategies to continually enhance quality
  • Protocols, order sets, and other key interventions
GOAL

To educate participants on opioid safety and glycemic control by emphasizing the use of best practices through training and resources.

TARGET AUDIENCE

Physicians, advanced clinical practitioners, professionals (PAs, NPs), pharmacists, RNs caring for patients at risk of thrombosis or needing treatment for thrombosis.

LEARNING OBJECTIVES
  1. Through didactic and interactive teaching methodology, participants will learn the current guidelines and evidence based approach to managing anticoagulation. The indications for peri-procedural management of anticoagulation in hospitalized patients will be discussed along with identification of factors that increase bleeding risk. Identifying patients at risk and utilizing standardize risk assessments will provide better treatments for hospitalized patients.
  2. Participants will be able to integrate current evidence based practice into their care for patients requiring anticoagulation Clinicians will gain an understanding of thrombotic and bleeding risk assessment as well a proper agent selection. A provider should know how to minimize the risk of using anticoagulants and become comfortable utilizing new anticoagulants during hospitalization.
  3. Participants will follow guidelines and provide evidence based care for their patients requiring anticoagulation. Participants will be able to avoid adverse drug effects including bleeding. Patient’s peri-procedural anticoagulation will be managed in accordance the individual risk: benefit ratio for that patient. Providers will then be able to use oral anticoagulants to decrease risk of DVT/PE as well as minimized adverse drug events by properly monitoring patients utilizing them.
CME INFORMATION

Accreditation Statement:
The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement:
The Society of Hospital Medicine designates this live activity for a maximum of 6 AMA PRA Category 1 CreditTM.  Physicians should only claim credit commensurate with the extent of their participation in the activity. 

Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Participation (non-CME)
Course opens: 
05/16/2018
Course expires: 
05/16/2021
Non-member cost:
$0.00
Rating: 
0

New York City, May 16, 2018

Syracuse, May 24, 2018

Kim Zammit, PharmD, BCPS, BCCCP, FASHP

Kim Zammit reports having no relevant financial or advisory relationships with corporate organizations related to this activity.     

Dave Coriale, Pharm D, BCPS

Dave Coriale reports having no relevant financial or advisory relationships with corporate organizations related to this activity.     

David Rosenberg, MD, MPH, FACP, SFHM

David Rosenberg reports the following:

  1. Advisory Committee/Board
    1. Nabrivia
    2. The Medicines Company
    3. Portola
  2. Research Grants/Contracts
    1. Janssen

Available Credit

  • 6.00 AMA PRA Category 1 Credit™
  • 6.00 Participation (non-CME)

Accreditation Period

Course opens: 
05/16/2018
Course expires: 
05/16/2021

Price

Non-member cost:
$0.00
Please login or register to take this course.

Click start to begin your evaluation.